Floatz logo

TIL

Melanoma, Uveal

Udai KammulaCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Melanoma, Uveal cohort.

Asset / SponsorPhaseRating
LENVATINIB
Providence Health & Services
Phase 2CCC
Adoptive Therapy With Autologous Mc2 Tcr T Cells
Erasmus Medical Center
Phase 1/2CCC
[68ga]vmt02
Perspective Therapeutics
Phase 1CC
[203pb]vmt01
Perspective Therapeutics
Phase 1CC

Same molecule, other indications

TIL is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian cancerDormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →